Background: Dupilumab is an IL-4 receptor a mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases. Objective: This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers of patients with moderate-to-severe atopic dermatitis (AD). Methods: Skin biopsy specimens and blood were evaluated from 54 patients randomized 1:1 to weekly subcutaneous doses of 200 mg of dupilumab or placebo for 16 weeks. Results: Dupilumab (vs placebo) significantly improved clinical signs and symptoms of AD, was well tolerated, and progressively shifted the lesional transcriptome toward a nonlesional phenotype (weeks 4-16). Mean improvements in a meta-analysis-derived AD transcriptome (genes differentially expressed between lesional and nonlesional skin) were 68.8%
Atopic dermatitis (AD) is a common inflammatory skin disease of increasing prevalence that affects 3% to 10% of adults and 10% to 20% of children globally. [1] [2] [3] [4] [5] The disease is moderate to severe in up to one third of patients, many of whom require systemic treatment. 6, 7 The profound symptom burden, systemic inflammation, and comorbidities in patients with moderate-to-severe AD [8] [9] [10] [11] [12] [13] [14] [15] have a substantial effect on the quality of life of patients and their families and present a large burden to health care systems. [16] [17] [18] [19] Therapeutic options are limited for patients with moderate-tosevere AD who had an inadequate response to topical treatments. They include phototherapy (narrow-band UVB [NB-UVB] or UVA1) and immunosuppressants (oral corticosteroids, cyclosporin A [CsA] , and others), [1] [2] [3] [4] [5] 7, 20 which have variable efficacy and are associated with multiple adverse effects on long-term use. Therefore there has been a large unmet need for safe and effective treatments for this patient population.
Dupilumab is the first targeted biologic agent approved in the European Union, United States, Japan, and other countries for the treatment of adults with inadequately controlled moderate-tosevere AD. It is a fully human VelocImmune-derived mAb 21, 22 targeting IL-4 receptor a (IL-4Ra), the shared subunit of the type 2 cytokines IL-4 and IL-13, inhibiting signaling of both cytokines. In clinical trials dupilumab consistently showed robust efficacy and acceptable safety in adults with moderate-to-severe AD, asthma, chronic rhinosinusitis with nasal polyposis, or eosinophilic esophagitis, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] supporting the notion that these atopic disorders share a type 2-centered pathogenesis.
Although preliminary data suggest that other type 2 antagonists targeting IL-13 or IL-31 receptor A might be beneficial in patients with AD, [35] [36] [37] these effects seem less robust than those of dupilumab, suggesting dual inhibition of IL-4 and IL-13 might be necessary for optimal control of moderate-to-severe AD. The limited efficacy of other type 2 immune inhibitors, such as mepolizumab (anti-IL-5) and omalizumab (anti-IgE), also supports IL-4 and IL-13 as critical mediators of AD pathogenesis. [38] [39] [40] [41] [42] [43] Targeting other pathways, such as the T H 17/IL-23 or T H 22 pathways, with ustekinumab (anti-IL-12/23 p40) or fezakinumab/ILV-094 (anti-IL-22) has been less efficacious relative to what has been observed in dupilumab AD trials to date. 44, 45 Scientific evidence supports the view of AD as a systemic immune-driven disease similar to psoriasis, another common inflammatory skin disease. [7] [8] [9] 11, 23, [46] [47] [48] [49] Both diseases are characterized by induction of polar cytokine pathways, with psoriasis viewed primarily as T H 17/IL-23 driven, whereas type 2 pathways predominate in patients with AD. Signals of the T H 22, T H 17, and T H 1 axes are also observed in patients with AD, but their role in pathogenesis is not proved. [50] [51] [52] [53] AD and psoriasis also have significant epidermal alterations, including increased epidermal hyperplasia and upregulated epidermal expression of antimicrobial proteins (S100A7/ S100A8/S100A9). AD is uniquely characterized by suppression of terminal differentiation markers in lesional and nonlesional skin. 7, 54, 55 In patients with psoriasis, increased understanding of pathogenic pathways led to rapid development of multiple biotherapeutics, 7, [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] which in turn demonstrated the relation between immune suppression and reversal of epidermal pathology. 58, 60, 61, 67 The cytokines IL-4 and IL-13 were suggested to have direct effects on the epidermis in patients with AD, including (1) inhibition of terminal differentiation with potential for feedback hyperplasia (keratinocyte hyperproliferation), 1, 3, 57, [68] [69] [70] [71] [72] (2) induction of spongiosis, 73 (3) inhibition of lipid synthesis, 73 (4) inhibition of synthesis of antimicrobial peptides, [74] [75] [76] [77] and (5) promotion of binding and colonization by Staphylococcus aureus. 78 IL-4 and IL-13 have also been suggested to induce type 2 activation and differentiation of dendritic cells (DCs), promote B-cell activation and IgE class-switching, and recruit eosinophils. [79] [80] [81] Systemic upregulation of type 2 inflammation in patients with AD has also been demonstrated by increased serum concentrations of CCL17 (thymus and activation-regulated chemokine [TARC] ), CCL18 (pulmonary and activation-regulated chemokine [PARC]), eosinophilic cationic protein (ECP), and periostin, which correlated with AD severity. [82] [83] [84] [85] [86] [87] [88] [89] Most patients with AD (or other atopic diseases) have increased IgE levels and antigen-specific IgE sensitization, as demonstrated by increased serum concentrations of various IgEs specific to common allergens (eg, house dust mite, staphylococcal enterotoxins, cat and dog dander, Cladosporium species, and grass). [90] [91] [92] [93] [94] [95] Nevertheless, although higher concentrations of total and specific IgEs have been associated with higher clinical AD severity at baseline, 11, 90 treatment with broad-target agents, such as CsA or phototherapy, does not consistently reduce IgE levels, an observation suggesting that these treatments do not adequately suppress IL-4 and IL-13 activity 47, 96, 97 and might even lead to increased IgE levels. 98 Previously, we reported that in a short (4-week) phase 1b trial, inhibition of type 2 inflammation with dupilumab modifies However, that trial was conducted in only a small number of patients across several dupilumab dose and placebo groups, and it lacked cellular correlates and long-term evaluations of genomic and cellular markers. 46 We now present results from a larger 16-week study evaluating the efficacy and safety of dupilumab in patients with moderate-tosevere AD, with a focus on the effect of treatment on molecular and cellular phenotypes of lesional and nonlesional skin biopsy specimens and on systemic type 2 biomarkers. Treatment with dupilumab (compared with placebo) progressively improved clinical AD severity and resulted in molecular suppression of AD genomic and cellular measures of inflammation and systemic type 2 biomarkers as early as week 4, and continued improvement beyond 16 weeks of treatment included reversal of AD-associated epidermal pathology.
METHODS

Study design
This was a randomized, placebo-controlled, double-blind, phase 2 trial (ClinicalTrials.gov: NCT01979016) conducted at 5 medical centers in the United States and Canada to assess the efficacy and safety of dupilumab compared with placebo in patients with moderate-to-severe AD. Molecular and cellular phenotypes of lesional and nonlesional skin and pharmacodynamic effects on serum type 2 biomarkers were evaluated. Patients (54/66 screened) were randomized 1:1 to weekly subcutaneous injections of 200 mg of dupilumab or placebo after a 400 mg loading dose or placebo on day 1, for a total of 16 weeks. The 16-week treatment period was followed by a 16-week safety follow-up period (until week 32).
The study was conducted in accordance with current US Food and Drug Administration regulations and guidelines and International Conference on Harmonization guidelines on Good Clinical Practice; all participants provided written informed consent under institutional review board approved protocols before participation (additional information is available in the Methods section in this article's Online Repository at www.jacionline.org).
Patients
Eligible patients were 18 years old or older, had moderate-to-severe AD (Eczema Area and Severity Index [EASI] score > _16 at baseline) chronically for 3 or more years, and had an inadequate response to topical medications within 6 months before screening. Use of topical corticosteroids or calcineurin antagonists was prohibited 1 week before and during the study. Patients were allowed to use only bland topical emollients during the study. Oral immunosuppressant agents and phototherapy were prohibited for 4 weeks before and during the trial (see the Methods section in this article's Online Repository for additional details).
Study end points
Efficacy end points included mean percentage change from baseline to week 16 in EASI scores (primary end point) and peak pruritus numeric rating scale scores and proportions of patients achieving reductions of 50% or greater, 75% or greater, and 90% or greater from baseline in EASI and SCOring Atopic Dermatitis (SCORAD) scores at week 16. Additional efficacy end points included mean (percentage) changes from baseline to week 16 in total SCORAD score, Patient-Oriented Eczema Measure score, and total Global Individual Signs Score and Global Individual Signs Score components. All efficacy end points are reported in detail in Table E1 in this article's Online Repository at www.jacionline.org.
Safety was assessed from baseline through week 32 based on the incidence of treatment-emergent adverse events (TEAEs; see Table E2 in this article's Online Repository at www.jacionline.org). Exploratory assessments included genomic changes in active AD lesions and changes in the AD transcriptome defined by gene expression differences between lesional and nonlesional skin and assessment of effects of dupilumab treatment on epidermal hyperplasia, as defined by changes in epidermal thickness (ET), keratin 16 (K16) expression or Ki67 1 cells, and inflammatory cells in tissues. [46] [47] [48] 100 An exploratory assessment was also conducted of treatment-related changes in the serum biomarkers CCL17, CCL18, periostin, ECP, total IgE, and allergen-specific IgEs (gray alder, Alternaria tenuis, Bermuda grass, silver birch, cat dander, Cladosporium species, German cockroach, Dermatophagoides farinae, dog dander, elm, Johnson grass, white oak, ragweed, sage mugwort, Timothy grass, white ash, staphylococcal enterotoxin A, and staphylococcal enterotoxin B).
Assessments
Biopsy and blood collection. Biopsy specimens (6 mm) were collected from lesional and nonlesional skin at baseline and at weeks 4 (lesional skin only) and 16. Blood samples were collected at similar time points. Posttreatment biopsy specimens were taken from the same location as pretreatment biopsy specimens approximately 1 cm from prior biopsy scars. All skin and blood analyses were performed while investigators were blinded to treatment allocation.
Immunohistochemistry. Immunohistochemistry was performed on frozen OCT-embedded cryostat tissue sections by using purified mouse anti-human mAbs, as previously described (see Table E3 in this article's Online Repository at www.jacionline.org). 48, 54 ET was measured by using computer-assisted image analysis software of hematoxylin and eosin-stained sections (ImageJ 1.42 software; National Institutes of Health, Bethesda, Md), as previously described. 47 Quantitative real-time PCR and gene-array analysis.
RNA was extracted, followed by hybridization to Affymetrix Human U133Plus 2.0 gene arrays (Affymetrix, Santa Clara, Calif) or by using quantitative real-time PCR (qRT-PCR), as previously described (see Table E4 in this article's Online Repository at www.jacionline.org).
48,100 Expression of target genes was determined by using qRT-PCR and normalized to the housekeeping gene human acidic ribosomal protein for analyses.
Circulating biomarkers. Levels of serum total and allergen-specific IgE and ECP were measured by using the ImmunoCAP method. 101, 102 Only patients with positive results (> _0.1 kU/L) for allergen-specific IgEs at baseline were included in IgE analyses. Serum CCL17 and CCL18 levels were measured by using Quantikine ELISA kits (R&D Systems, Minneapolis, Minn), and periostin levels were measured by using the R&D Systems DuoSet ELISA kit.
Statistical analyses
Sample size was determined to achieve 79% power to detect a 40% difference between dupilumab and placebo with respect to percentage change in EASI score from baseline to week 16, assuming the common SD is 50% with a 2-sided test at the .05 significance level.
All clinical and circulating biomarker analyses were performed by using SAS (SAS Institute, Cary, NC). Analysis of secondary efficacy end points and exploratory variables were not adjusted for multiplicity, and thus nominal P values are provided. Additional details of the analyses performed are reported in the Methods section in this article's Online Repository.
RNA, serum, and correlation analyses were performed in Bioconductor R packages (open source software available from www.bioconductor.org). Linear mixed-effect models were used to assess treatment changes in log 2 -transformed qRT-PCR measurements (normalized to human acidic ribosomal protein), with tissue (lesional/nonlesional) and its interaction with time as a fixed factor. qRT-PCR values of less than the limit of detection were imputed as 20% of the minimal value over the limit of detection. Missing values for all mechanistic data were not imputed. The histologic score is a combined score of ET and mRNA expression of K16, as obtained by averaging the z score of both measures.
Quality control of microarrays used standard metrics and R package microarray quality control. Images were scrutinized for spatial artifacts by using Harshlight (Bioconductor). 103 Expression measures were obtained by using the GC Robust Multi-array Average algorithm. 104 Probe sets with expression of greater than 3 in at least 15 samples were kept for analyses. Expression values were modeled by using mixed-effect models, with treatment and time as fixed factors and a random effect for each patient. Fold changes (FCHs) for comparisons of interest were estimated, and hypothesis testing was conducted with contrasts under the general framework for linear models in R limma package. P values from moderated (paired) t tests were adjusted for multiple hypotheses by using the Benjamini-Hochberg procedure, which controls the false discovery rate (FDR). 105 Genes with FDR of less than 0.05 and FCH of 2 or greater were declared differentially expressed. Hierarchical clustering of mean expression profiles was performed with Euclidean distance and a McQuitty agglomeration scheme. 54, 104 AD-associated immune or barrier gene subsets were quantified by using Gene Set Variation Analysis, an unsupervised sample-wise enrichment method that produces a score of activity for a gene subset or pathways for each sample. 106 Modeling was performed by using the same approach described for genes, including adjustment for multiplicity. The association of biomarkers and gene sets with clinical responses was evaluated by using Spearman correlation coefficients. An unsupervised clustering analysis using Spearman correlation and a McQuitty agglomeration scheme is presented.
RESULTS Patients
Of 66 patients screened, 54 (81.8%) were randomized to receive 200 mg of dupilumab every week (n 5 27) or placebo every week (n 5 27). Most patients in the placebo (25/ Table E5 in this article's Online Repository at www.jacionline.org).
Skin biopsy specimens for exploratory analyses were available for analysis from 27 patients in the dupilumab group and from 25 patients in the placebo group. Numbers of lesional and nonlesional samples collected at baseline, week 4, and week 16 from dupilumab-and placebo-treated patients available for analyses are reported in Table E6 in this article's Online Repository at www.jacionline.org. The number of serum samples collected at baseline, week 4, and week 16 from dupilumab-and placebotreated patients available for analyses are provided in Table E7 in this article's Online Repository at www.jacionline.org.
Efficacy
Dupilumab, compared with placebo, significantly improved measures of clinical efficacy at week 16, including EASI scores (P <.0001; see Table E8 and Fig E2, A, in this article's Online Repository at www.jacionline.org) and peak pruritus numeric rating scale scores (P 5 .003; see Table E8 and Fig E2, D) . Proportions of patients with reductions of 50% or greater, 75% or greater, and 90% or greater from baseline in EASI scores at week 16 were also significantly greater with dupilumab than placebo (see Fig E2, B ). An illustration of clinical improvement with dupilumab in representative patients is shown in Fig E2, C. Dupilumab also significantly improved other clinical outcomes relative to placebo, except for the proportions of patients with reductions of 75% or greater and 90% or greater from baseline in SCORAD scores (see Table E8 ).
Safety
The overall incidence of TEAEs was generally similar in the 2 study groups: 24 (88.9%) patients in the dupilumab group versus 23 (85.2%) patients in the placebo group (see Table E2 ). No deaths were reported in the study. The incidence of serious TEAEs was numerically greater in the placebo group than in the dupilumab group, whereas the incidence of TEAEs resulting in permanent treatment discontinuation was similar in the 2 treatment groups (see Table E2 ). The most common TEAEs reported in this study are shown in Table E2 .
Suppression of inflammatory cell infiltrates in dupilumab-treated skin
Immunostaining was performed to measure cellular infiltrates of CD3 1 cells were significantly reduced from baseline at week 16 with dupilumab (P < .05 for mean percentage change from baseline and vs placebo). There were no significant differences between treatment groups in CD8 1 or CD1b 1 T cells or in CD83 1 DCs (see Table E9 ). Nonlesional skin, which had significantly less increased infiltrates relative to control tissues at baseline, also showed no significant differences (data not shown).
Progressive shift of AD molecular phenotype from lesional to nonlesional Affymetrix U133Plus 2.0 gene arrays (Affymetrix) were performed to define the AD skin phenotype or transcriptome at baseline (differentially expressed genes between lesional and nonlesional skin). Criteria of FCH of 2 or greater and FDR of less than 0.05 were used. These differentially expressed genes were used to assess the overall effects of dupilumab versus placebo on the AD transcriptome. In samples from patients with AD collected in this study, the baseline transcriptome of lesional versus nonlesional skin was defined by 527 upregulated and 508 downregulated probes in the placebo group and 411 upregulated and 336 downregulated probes in the dupilumab group (Fig 1, A) .
At week 16, no gene probes in the dupilumab group met the statistical criteria for being differentially regulated, whereas in the placebo group the number of differentially regulated gene probes increased relative to baseline (Fig 1, A and B) . Overall, dupilumab significantly altered gene expression in lesional skin at both weeks 4 and 16 versus baseline; there was no comparable modulation in placebo-treated patients.
Similar genomic changes with dupilumab (vs placebo) were observed after evaluating a recently published, robust, metaanalysis-derived atopic dermatitis (MADAD) transcriptome derived from a meta-analysis of multiple study transcriptomes. 107 Based on the MADAD transcriptome, significantly altered gene expression (vs baseline) was already evident in lesions of dupilumab-treated patients at week 4, with a further shift to a more nonlesional phenotype at week 16 (red-to-blue or blue-tored transitions; Fig 1, C) . At week 16, lesions from dupilumabtreated patients had expression levels similar to those of nonlesional skin. No major changes were seen in lesions from placebo-treated patients at week 4 versus baseline, whereas some changes were noted in placebo-treated AD lesions at A and B, Numbers of differentially expressed genes (DEGs) with criteria of an FCH of greater than 2 and FDR of less than 0.05 upregulated (Up) and downregulated (Down) at baseline (W0) and week 16 (W16) in lesional (LS) versus nonlesional (NL) skin in the placebo and dupilumab groups and number of genes differentially modified in LS skin at week 4 (W4) and week 16 versus baseline in the study transcriptome (Fig 1, A) and the MADAD transcriptome (Fig 1, B) . C, Heat map of the MADAD transcriptome with comparisons to healthy subjects (Normal). Sample data are ordered at each time point and tissue type by decreasing EASI score (indicated by the gray scale bar; black indicates highest EASI score, and white indicates lowest EASI score). D, Overall percentage improvement in the MADAD transcriptome at W4 and W16 is shown. ***P < .001 at both time points for dupilumab versus placebo comparison. E, Effect of dupilumab on expression of genes upregulated (red) or downregulated (blue) in lesional versus nonlesional skin in the MADAD transcriptome. Blue bars superimposed on the plots represent means 6 SEMs. week 16 (Fig 1, C , and see Table E10 in this article's Online Repository at www.jacionline.org).
With dupilumab treatment, there were mean genomic improvements in the MADAD transcriptome of 68.8% (73.8% decreases in upregulated genes and 59.7% increases in downregulated genes) at week 4 and 110.8% (120.1% decreases in upregulated genes and 93.7% increases in downregulated genes) at week 16 (P < .001 vs placebo; Fig 1, D) . In placebo-treated patients we observed a worsening of lesional skin by 10.5% to a more lesional molecular phenotype (6.7% increase in upregulated genes and 17.3% decrease in downregulated genes) in the MADAD transcriptome at week 4, with an overall improvement of 55.0% (59.2% decreases in upregulated genes and 47.1% increases in downregulated genes) at week 16 (Fig 1, D) . Fig 1, E, shows the dupilumab-induced reversal of the baseline genomic dysregulation between lesional and nonlesional skin of patients with AD (in both upregulated and downregulated genes) at weeks 4 and 16 versus minimal changes with placebo.
Dupilumab suppression of type 2, T H 17, and T H 22 inflammatory pathways in lesional skin
As measured by using microarray expression profiling, dupilumab showed significant modulation at week 4 and progressive suppression through week 16 of key immune genes in the MADAD transcriptome. [46] [47] [48] 107 These included genes related to inflammatory proteases (MMP12, SERPINB4 [SCCA1/2], MMP3, and MMP1), DCs (CD1b, ITGAX/CD11c, and CD1c), T-cell activation (granzyme B, ICOS, and CCR7), the type 2 pathway (CCL26, IL13RA2, CCL17, CCL18, CCL13, CCL22, and DPP4), the T H 17/ T H 22 pathway (CXCL1/CXCL2, LCN2, and S100A9/S100A12), and negative regulators (CTLA4; Fig 2 and see Table E10 ). To more accurately quantify low-expressing genes not always captured on microarrays, we also performed qRT-PCR; representative markers of the various immune axes associated with AD were included. Highly significant reductions in mRNA expression of the general inflammatory marker MMP12 were seen in dupilumab-versus placebotreated lesional and nonlesional skin at both weeks 4 and 16 ( Figs 3 and 4) . As expected, dupilumab significantly suppressed mRNA expression of genes of type 2 inflammation regulated by IL-4Ra-mediated signaling (Figs 3 and 4 and see Fig E4 in this article's Online Repository at www.jacionline.org). Robust and significant reductions in expression of the type 2-polarizing chemokines CCL13/monocyte chemoattractant protein 4, CCL18/PARC, CCL26/Eotaxin-3, CCL17/TARC, and CCL22/ macrophage-derived chemokine were observed in lesional skin at weeks 4 and 16. A reduction of IL13 gene expression at week 16 (P < .01 vs baseline and P < .10 vs placebo) was also observed. Dupilumab, but not placebo, reduced expression of the itch-associated cytokine IL-31 (P < .05 vs baseline at week 16) and the regulatory cytokine IL-10 (P < .001 vs baseline and vs placebo at week 16) in lesional skin (Figs 3 and 4) . Progressive suppression of the T H 9 cytokine IL-9 was observed in lesions treated with dupilumab but not placebo (P < .001 vs baseline for dupilumab at week 16). No significant changes were noted in expression of the T H 1/IFN-g markers IFN-g and CXCL10 in skin from dupilumab-treated patients, as measured by using qRT-PCR. Consistent with array results, dupilumab also significantly suppressed mRNA expression of T H 17-and T H 22-regulated genes in lesional skin, including IL17A (P < .05 vs placebo at both weeks 4 and 16), CXCL1 (P < .001 vs baseline and P < .01 vs placebo), PI3, IL22, and the IL-17/IL-22-regulated S100A9 and S100A12 (P < .001 vs baseline and P < .05 vs placebo; Figs 2-4 and see Fig E4) . Expression of several genes decreased from baseline in nonlesional skin by week 16, including LCN2, PI3, CCR1, S100A9, ITGAX, CD1b, CCL17, CCL22, CCL18, MMP12, and CCL26; Fig 2) . No significant changes from baseline with dupilumab were observed in mRNA expression of IL4, IL5, IL1B, FOXP3, IL23p40, or CCL20. IL23p19 expression was significantly reduced with dupilumab (vs placebo) at week 4 (P < .05), but this result was not replicated at week 16 (Fig 4  and see Fig E4) .
Reversal of epidermal responses with dupilumab
Compared with placebo, dupilumab significantly modulated genes related to epidermal pathology in patients with AD, including reduced epidermal proliferation measures (MKi67, K16, IL24, and IL26) and increased lipid metabolism and barrier junction genes (ELOVL3, FAR2, claudin 8 [CLDN8], CLDN23, and aquaporin 9 [AQPN9]), which often are downregulated in AD lesions. 46, 50, 54, 107 These changes were particularly evident at week 16 (see Table E10 ).
Changes in epidermal hyperplasia were evaluated in dupilumab-and placebo-treated AD tissues by assessing changes from baseline at weeks 4 and 16 in ET and keratinocyte proliferation markers (K16 protein immunostaining and mRNA expression by using RT-PCR and Ki67 1 cellular counts) (Fig 5, A-F) . Consistent with the transcriptome-profiling results, median (quartile 1-quartile 3) ET of lesional skin at baseline was similar in the dupilumab (128 mm; quartile 1-quartile 3, 99.3-156.0 mm) and placebo (125 mm; quartile 1-quartile 3, 106.0-172.4 mm) groups. Robust decreases from baseline in median lesional ET of 223% (week 4) and 244% (week 16) were observed with dupilumab treatment versus median changes from baseline of 25% (week 4) and 14% (week 16) in the placebo group. The difference in ET reduction between the dupilumab and placebo groups was statistically significant at both weeks 4 and 16 (P < .01 at both time points; Fig 5, A and D) . No significant changes were noted in the ET of nonlesional skin (median, Fig 5, A) , K16 (Fig 5, B) , and FLG (Fig 5, C) . D, Median percentage change in ET at week 4 (W4) and week 16 (W16) versus baseline in lesional skin (6 first and third quartiles). E, FCH of K16 mRNA expression in lesional and nonlesional skin at weeks 4 and 16 versus baseline. 
28% [218.3%, 4.8%] in the dupilumab group vs 21%
[214.9%, 43 .7%] in the placebo group, P 5 .55; Fig 5, A) . Significant reduction in K16 mRNA expression was observed in lesional skin of dupilumab-versus placebo-treated patients at week 4 (P < .001) and week 16 (P < .05; Fig 5, E) . Qualitative assessment of K16 protein immunostaining confirmed the K16 mRNA results, with no significant change in K16 staining observed in the majority of patients in the placebo group, whereas most dupilumab-treated patients progressively lost the K16 staining through week 16 (the number of K16-positive patients out of the total number of patients treated with dupilumab or placebo at each week is provided; Fig 5, B) . Significant reductions from baseline in Ki67 1 cell counts were also observed in lesional skin of dupilumab-treated patients at week 4 (median, 251% [quartile 1-quartile 3, 283.28% to 216.84%) versus baseline (P 5 .0074), but not at week 16 (262% [284.77% to 0.36%]) versus baseline (P 5.2979; Fig 5, F and Table E9 ). The reductions were not statistically significant in placebo-treated patients at week 4 (110.7%; 215.13, 87.80) versus baseline (P 5 .1434) and at week 16 (220.7%; 236.44, 3.17) versus baseline (P 5 .1016). However, the differences were statistically significant with dupilumab versus placebo at week 4 (P 5 .0013) and at week 16 (P 5 .0062; Fig 5, F and Table E9 ).
Increased expression of epidermal terminal differentiation markers with dupilumab treatment
Areas with a lesional phenotype before treatment were characterized by discontinuous and relatively faint expression of filaggrin (FLG; Fig 5, C) . After 16 weeks of dupilumab treatment, FLG showed stronger and more continuous granular layer expression in samples from areas that had been lesional at baseline (Fig 5,  C) . Baseline mRNA expressions of both FLG and loricrin (LOR) are reduced in AD lesional versus nonlesional skin, 47, 54, 72 with significant increases (vs baseline) with dupilumab treatment (P <.01) in lesional mRNA expression of both genes to levels similar to that in nonlesional skin at week 16 (Fig 5, G, and see Fig E5, A, in this article's Online Repository at www.jacionline.org). These increases were even more pronounced when adjusted for the reduction in epidermal hyperplasia (as measured by changes in K16 mRNA expression; Fig 5, H, and see Fig E5, B) .
Correlation of biomarkers with clinical improvement and reductions in epidermal hyperplasia with dupilumab
We identified markers associated with improvements in clinical, molecular, and histologic measures of AD by (Fig 6, A) and histologic score (composite z score of ET and K16) improvement (Fig 6, B) . C, Heat map of Spearman correlation matrix of measured values at week 16 ordered by unsupervised clustering (and shown by dendrogram).
determining correlations of each marker measured in lesional skin using qRT-PCR and immunohistochemistry, and serum biomarkers, with improvements in EASI and SCORAD (clinical disease reversal) scores and reductions in epidermal hyperplasia (histologic disease reversal, as measured based on a combined histologic score of ET and mRNA expression of K16; Fig 6) . Spearman correlation coefficients of skin and serum biomarkers with percentage change in clinical scores (EASI and SCORAD) and histologic score improvements at week 16 are shown in Fig 6, A and B , respectively. A heat map showing the relations between biomarkers and with disease scores at week 16 is shown in Fig 6, C. SCORAD and EASI disease activity measures were highly correlated with each other and with the histologic score improvement at week 16 (Fig 6, A and B) . Strong, statistically significant, and direct correlations of the hyperplasia-related measures of epidermal proliferation (Ki67 1 cells) and histologic score (P < .01) were observed with percentage change from baseline in EASI scores at week 16 (Fig 6, A) . The Ki67 1 cell count was also highly correlated with histologic score improvement at week 16 (Fig 6, B) . Numbers of FcεRI 1 and CD206 1 DCs and mRNA expression levels of IL5, IL31, IL9, and the IL-22/IL-17-regulated genes (S100A8, S100A12, S100A7, and PI3) in the skin were also highly correlated (correlation defined as r > _ 0.2 and P < .05) with the percentage change from baseline in EASI score at week 16 (Fig 6, A) . Expression of PI3, S100A12, S100A8, and IL31 was also strongly correlated with histologic improvement (Fig 6, B) . The reduction in serum CCL18 expression was highly correlated with the percentage change from baseline in EASI score at week 16 but not with histologic score improvement. CD11c 1 cells and IL-12/23p40 expression were correlated with histologic scores but not the percentage change from baseline in EASI score at week 16 (Fig 6, A and  B) . Of note, increases in differentiation markers (FLG and LOR, P < .05) were negatively correlated with histologic scores but not with the percentage change from baseline in EASI scores at week 16 (Fig 6) .
Dupilumab induced progressive improvements in inflammatory and barrier responses
We evaluated the effect of dupilumab compared with placebo treatment on expression of previously reported gene signatures [46] [47] [48] 108 for upregulated and downregulated genes in the AD transcriptome of genes identified in genome-wide association studies of AD. 109 These genes include keratinocyte, T-cell, and DC gene subsets; primary cytokine-treated keratinocytes; epidermal differentiation complex (EDC) genes; and other genes from specific immune pathway subsets or their superenhancers (Fig 7, A) . 46, 107, 108, [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] Only modest improvements were observed in most gene signatures in placebo-treated lesional skin at week 16, with either no improvement or more inflammatory molecular phenotypes at week 4. Dramatic improvements (sometimes exceeding 100%) were observed in dupilumabtreated patients at week 16, with changes already evident at week 4. For example, the gene subsets from untreated keratinocytes and keratinocytes treated with IL-4 46 showed greater than 100% improvement after 4 weeks of treatment with dupilumab compared with placebo. In addition, almost complete improvement toward a more nonlesional molecular phenotype was seen at week 4 in the EDC gene signature. 46, 50, 55, 74 Dupilumab induced significant progressive changes through week 16 that extended beyond the expected type 2 pathway, including suppression of key AD responses in lesional skin (eg, T H 22 and T H 17 pathways) and in cytokine-treated keratinocytes, including innate cytokines. 46, 74, 107, 108, 111, 120 Overall, expression signatures of keratinocytes treated with IL-1, TNF-a, or IFN-g at week 16 were markedly reduced with dupilumab relative to baseline, 46, 118 although similar reductions in IFN-g at week 16 were seen with both dupilumab and placebo. Mean FCH reductions in selected gene signatures in AD lesional and nonlesional skin, including upregulated genes in the MADAD transcriptome; immune genes; and T H 2-, T H 17-, and T H 1-specific genes (Fig 7, B) were significantly greater with dupilumab but not placebo.
Dupilumab suppressed circulating markers of type 2 inflammation
Dupilumab (vs placebo) significantly reduced circulating serum concentrations of CCL17, CCL18, and periostin from baseline through week 16 (see Fig E6 and Table E11 in this article's Online Repository at www.jacionline.org). Dupilumab also progressively and significantly reduced total IgE concentrations (see Fig E6 and Table E11 ), as well as concentrations of multiple allergen-specific IgEs. These included allergen-specific IgEs previously associated with AD and other atopic or allergic type 2 manifestations (eg, staphylococcal enterotoxin A, 261% vs 0%; Dermatophagoides farinae, 239% vs 0%; see Table E12 in this article's Online Repository at www.jacionline.org). [90] [91] [92] [93] [94] [95] Although concentrations of most specific IgEs were significantly reduced only with dupilumab (except that of sage mugwort [Artemisia vulgaris], P 5 .10), particularly large (>50%) and significant reductions were seen in those of cockroach, staphylococcal enterotoxin A, Cladosporium species, Bermuda grass, silver birch, white oak, elm, white ash, Johnson grass, and cat dander (see Table E12 ). Baseline serum total IgE concentrations were greater than the normal range (119 kU/L) in both groups (see Table E5 ). The proportion of patients with relatively normal baseline IgE concentrations (<150 kU/L, n 5 10) who had positive results for at least 1 of the allergen-specific IgEs tested in the study was 20% (n 5 2).
DISCUSSION
The clinical efficacy of dupilumab in patients with moderateto-severe AD has proved the central role of IL-4 and IL-13 signaling in the pathogenesis of AD. In this study dupilumab targeting helps us better understand the specific pathways that drive AD and mediate its clinical benefit.
This study evaluated both short-term (4 weeks) and longerterm (16 weeks) effects of dupilumab-mediated IL-4Ra blockade on barrier and immune pathomechanisms in the skin of patients with moderate-to-severe AD. Clinical efficacy, safety, and suppression of type 2-related systemic biomarkers were also evaluated. This study demonstrated strong correlations between molecular, histologic, and clinical changes. Most previous studies of broad 121 immune suppressants (including CsA, methotrexate, and NB-UVB) assessed long-term clinical improvements in patients with moderate-to-severe AD but did not perform molecular and cellular correlation analyses in skin biopsy specimens. 4, 47, 48 Although CsA and NB-UVB have been shown to broadly modulate both immune (including type 2 pathway) and epidermal responses, these treatments have direct effects on keratinocytes and therefore cannot prove the pathogenic role of the type 2 axis in patients with AD. 47, 48 The clinical efficacy and safety of dupilumab monotherapy in this study was consistent with those observed in larger phase 3 AD trials. [24] [25] [26] [27] [28] Dupilumab significantly improved AD signs and symptoms, and injection-site reactions and conjunctivitis in this trial were more frequent with dupilumab than with placebo. Aggregated data from dupilumab studies in patients with AD 122 indicate an increased incidence (relative to placebo) of conjunctivitis; however, most cases of conjunctivitis were mild or moderate and resolved or were resolving during study treatment. Of note, a dupilumab-associated increase in conjunctivitis has not been seen in studies of dupilumab in patients with other indications, such as asthma 29, 30, 33, 34 and chronic rhinosinusitis with nasal polyposis. 31 The parallel, longer-term tissue reversibility of key AD epidermal and immune features with dupilumab treatment was not evaluated. We previously reported significant dose-dependent shifts of the AD transcriptome in patients with AD treated with 4 weeks of dupilumab compared with placebo. 46 Although that small study was the first to associate clinical improvement with suppression of type 2 and other inflammatory markers, it lacked histologic correlates of resolution of the AD-related epidermal pathology. Furthermore, it evaluated only a small number of patients after 4 weeks of treatment and did not address how specific inhibition of the type 2 pathway affects the AD molecular and cellular profiles with extended treatment. 23, 46 This is the most comprehensive study to establish the ability of dual inhibition of IL-4 and IL-13 signaling to modulate the immune response and epidermal barrier pathomechanisms that typify AD in addition to reversing clinical disease activity. It is also the first study to evaluate tissue responses around the time at which most patients have a maximal clinical response to dupilumab, thus allowing correlation of the extent of disease reversal in skin lesions and circulating markers with clinical responses. 25, 26 Compared with placebo, dupilumab progressively and significantly reduced cellular infiltrates, including CD3
1 T cells and various DC subsets, such as FcεRI 1 cells, in AD lesions at weeks 4 and/or 16. Dupilumab also induced a strong, rapid, and significant improvement (68.8%) in a robust genomic AD signature, the MADAD transcriptome, 107 after only 4 weeks of treatment, whereas a 10.5% worsening of the AD transcriptome was observed in the placebo group. Progressive modulation of the lesional AD expression profile was achieved at week 16, with an improvement of 110.8% in the dupilumab group but only 55% in placebo-treated patients. This improvement in the placebo group could be explained in part by the much higher dropout rate caused by lack of efficacy in this group. Placebo-treated patients who did not experience relief or even experienced disease exacerbation might have been more likely to drop out of the trial after week 4 but before reaching the 16-week time point. Therefore the placebo group patients remaining at week 16 perhaps represent those with particularly favorable responses to placebo. At week 16, we observed a reversal of the lesional AD phenotype to a level beyond even that of nonlesional skin, and we observed a large shift toward the nonlesional phenotype as early as week 4.
The ability of targeted IL-4Ra blockade with dupilumab to revert the AD skin transcriptome toward that of nonlesional skin is at least comparable with that achievable with a maximal dose of CsA, a broad T-and B-cell immune suppressant [123] [124] [125] [126] that is not approved for AD in the United States and use of which is limited because of toxicity.
Blocking IL-4Ra signaling with dupilumab progressively reversed the characteristic epidermal hyperplasia of AD lesions 1,7,55 after 4 and 16 weeks of treatment, as indicated by significant reductions in ET, Ki67 1 cells, and K16 protein and gene expression. In parallel, we observed significant increases in mRNA expression of terminal differentiation markers known to be downregulated in patients with AD, including FLG and LOR, and this was particularly evident after accounting for the concurrent decrease in epidermal proliferation (relative to K16 expression). These increases were coupled with protein localization of FLG that was more homogeneous than the faint and discontinuous staining observed at baseline. These results provide clinical evidence to support the hypothesis from in vitro and mouse experiments that IL-4 and IL-13 directly impair the skin barrier and suppress expression of FLG, LOR, and other EDC and lipid genes. [70] [71] [72] [73] Dupilumab treatment significantly increased expression of genes related to lipid metabolism (ELOVL3 and FAR2) and tight junction genes (claudins), genes previously found to be downregulated in AD lesions and also suppressed in vitro by type 2 cytokines. 46, 50, 54, 107, 127, 128 These results confirm previous analyses that showed a negative correlation between type 2 cytokine levels and lipid measures in patients with AD 107 and demonstrate the role of IL-4 and IL-13 in skin barrier dysfunction in patients with AD.
Dupilumab reversed key immune and barrier mechanisms dysregulated in AD skin, with effects extending beyond those expected from dual inhibition of IL-4 and IL-13 signaling, suggesting that chronic type 2 inflammation has secondary effects on other immune axes. Dupilumab potently inhibited type 2 pathway genes as early as week 4, with progressive reductions at week 16 (eg, IL13, CCL17, CCL18, and CCL26) and no comparable reductions in the placebo group. DPP4, an IL-13-regulated gene being explored as a potential predictive marker for IL-13-specific inhibition in patients with AD, was also downregulated at week 16. Aside from suppression of type 2 genes regulated by IL-4 and/or IL-13 signaling, as expected, dupilumab also significantly downregulated mRNA expression of inflammatory proteases (MMP12 and SERPINB4), T-cell activation (ICOS and CCR7), and T H 22 and T H 17 pathway genes (eg, IL17A, IL22, and S100As) after 4 and 16 weeks of treatment. Suppression of the T H 17/T H 22 axes correlated with clinical improvements and resolution of epidermal hyperplasia.
Although dupilumab's effects have proved that the type 2 pathway is central to AD pathogenesis, previous studies have shown that the T H 22 and T H 17 pathways can also play contributory roles in the AD phenotype and its epidermal pathology. 1, [3] [4] [5] 7, 20, 51, 53, 129, 130 However, consistent robust efficacy in patients with AD has been achieved only with dupilumab; inconclusive or less impressive results were obtained with anti-IL-17/ IL-23 and anti-IL-22/ILV-094 approaches, suggesting that these axes are not central pathogenic drivers relative to the type 2 axis. 44, 45 Future studies with specific IL-22, IL-17, and IL-23 antagonists should determine whether cytokines other than the type 2 IL-4 and IL-13 cytokines have a direct role in AD or are secondary inflammatory effects of chronic type 2 activation.
IL-22 has been linked to epidermal hyperplasia in patients with AD and to inhibition of keratinocyte terminal differentiation 120, [131] [132] [133] [134] [135] [136] and induction of the S100As, 120, 136 processes that further induce hyperplasia. 135, 136 IL-22 has also been implicated in expression of antimicrobial peptides and in reduction of S aureus colonization. 137 IL-17 strongly induces antimicrobial peptides, such as b-defensins, cathelicidin, and S100A8. 120, 134 In addition to IL-4, IL-17 can further inhibit some barrier measures that are downregulated in patients with AD, including FLG, LOR, and tight junctions 138, 139 ; it was recently implicated in epidermal proliferation. 140 IL-17 is also thought to play a role in host defense against S aureus, which in turn upregulates IL-17.
141,142 Reversal of histologic hyperplasia and/or improvement in AD disease activity with dupilumab treatment was significantly associated not only with reductions in expression of the S100A7, S100A8, and S100A12 genes, which have been shown to be induced by IL-17/IL-22, 120 but also with suppression of type 2/T H 2 measures in the skin (IL-31) and serum (CCL18/PARC). The significant negative correlation between the reduction in epidermal hyperplasia and increases in expression of the terminal differentiation genes LOR and FLG demonstrates an improvement in skin barrier integrity. Although the reduction in expression of T H 17/T H 22-related genes with IL-4/IL-13 inhibition is not entirely understood, they might result in part from suppression of IL-4/IL-13-mediated induction of DC differentiation 143, 144 and might reflect wider networks of inhibition resulting from expression of IL-4Ra on a variety of cells in skin (eg, keratinocytes, DCs, T cells, eosinophils, and mast cells). Data from a study in flaky-tail mice support the existence of IL-4/IL-17 coregulatory networks. 145 Although the type 2/T H 2 axis is common to all patient populations, various AD phenotypes, such as intrinsic, Asian, and especially pediatric AD, exhibit greater expression of T H 22 and T H 17 cytokines. 1, 3, 7, 130, [146] [147] [148] Dupilumab appears to have similar efficacy in pediatric and Japanese patients, thus supporting the notion that these other inflammatory pathways are secondary to type 2 inflammation. [149] [150] [151] [152] This study defined robust, progressive, tissue-transcriptional signatures of therapeutic response to dupilumab that could serve as a point of reference for future therapeutic studies across a variety of AD patient populations. It defines a set of skin and circulating biomarkers that correlate with dupilumab-mediated clinical improvements in AD across the atopic or ''allergic'' spectrum and/or epidermal hyperplasia. Many of these measures are key pathogenic elements of AD and have been linked to successful treatment responses with broad immune-targeting agents, such as CsA and even NB-UVB, in patients with AD. 11, 47, 48 These measures include significant associations between clinical improvement and type 2/T H 2 markers (eg, IL-13, CCL18, CCL17, CCL26) in the skin and circulation (CCL18, CCL17, and IgE), as well as T H 17/T H 22 pathway-related genes (eg, S100As, CXCL1, and PI3). Changes in markers of epidermal hyperplasia (ET, K16, Ki67, and histological score) and general inflammation (eg, MMP12) were also significantly associated with clinical improvement.
An additional exploratory analysis, which was not previously reported in the longer-term dupilumab studies, was to evaluate the effects of dupilumab on atopic or allergic and type 2 serum biomarkers. Circulating type 2 chemokines have been implicated as biomarkers of AD severity at baseline or as markers of treatment response, and they include CCL17, CCL18, ECP, and periostin. 11, 89, [153] [154] [155] [156] [157] [158] CCL17 and CCL18 are chemokines that attract and activate inflammatory cells expressing CCR4 and CCR8 receptors, whereas the extracellular matrix protein periostin amplifies keratinocyte responses. In our study dupilumab significantly suppressed serum levels of all of these biomarkers, as well as total and allergen-specific IgE concentrations. Although serum total and allergen-specific IgE concentrations were previously associated with greater severity of AD and other type 2 atopic/allergic diseases, [90] [91] [92] [93] [94] [95] broad-based treatments have largely failed to cause downregulation of IgE. 47, [96] [97] [98] Further studies are needed to evaluate the clinical effect on other atopic comorbidities of the dupilumab-induced modulation of circulatory type 2 biomarkers in our study.
Limitations of the current study include the fact that the dose and regimen investigated are different from the approved dose (300 mg every 2 weeks) and the regimens used in the larger phase 3 AD trials (300 mg weekly and 300 mg every 2 weeks), [25] [26] [27] [28] as well as the fact that analyses were conducted only to week 16. Overall, these data further confirm AD as a type 2-driven disease in which IL-4 and IL-13 have a central role. In addition, our results suggest that IL-4/IL-13 signaling contributes to regulation of the IL-17 and IL-22 cytokine networks in patients with AD, given the significant modulation of these pathways that results from IL-4Ra inhibition. These data demonstrate that inhibition of IL-4Ra, which results in dual inhibition of IL-4/IL-13 signaling, can effectively suppress key pathogenic processes in patients with AD, thus supporting the notion that cytokines induce and perpetuate the epidermal alterations in patients with AD. 2, 3, [68] [69] [70] 73, 120, 129, 132, 133, 136 In parallel with increased cytokine activation in skin lesions before treatment, [8] [9] [10] [11] 49 patients with severe AD have robust systemic cytokine induction, as reflected by the broad abnormalities already observed at the nonlesional skin level. 11, 54 Dupilumab significantly improves immune activation in both the skin and blood compartments in parallel with reversal of the pathologic epidermal responses and clinical disease activity. Future studies should also address interactions between the skin microbiome and resolution of clinical disease and tissue inflammation in patients with moderate-to-severe AD.
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Key messages
d Targeted dual inhibition of IL-4 and IL-13 signaling through anti-IL-4Ra blockade with dupilumab rapidly and progressively suppressed cellular and molecular cutaneous markers of inflammation from week 4 through week 16 and reversed associated epidermal abnormalities while improving disease severity scores and symptoms in patients with moderate-to-severe AD.
